Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cellectis S.A. (CLLS : NSDQ)

• Company Description    Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. Number of Employees: 222

• Price / Volume Information    Yesterday's Closing Price: $3.48 Daily Weekly Monthly 20 Day Moving Average: 212,731 shares Shares Outstanding: (millions) Market Capitalization: $193.43 (millions) Beta: 3.10 52 Week High: $5.48 52 Week Low: $1.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.57% 1.31% 12 Week 17.97% 8.35% Year To Date 93.33% 67.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 8 RUE DE LA CROIX JARRY - PARIS LLE-DE-FRANCE,I0 75013 FRA ph: 33-1-81-69-16-00 fax: 33-1-81-69-16-06 investors@cellectis.com http://www.cellectis.com

• General Corporate Information    Officers Andre Choulika - Chief Executive Officer and Co-Founder Jean-Pierre Garnier - Chairman of the Board and Director Arthur Stril - Chief Financial Officer & Chief Business Officer Laurent Arthaud - Director Pierre Bastid - Director Peer Information Cellectis S.A. (CORR.) Cellectis S.A. (RSPI) Cellectis S.A. (CGXP) Cellectis S.A. (BGEN) Cellectis S.A. (GTBP) Cellectis S.A. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15117K103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/03/25 Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: 3.10 Market Capitalization: $193.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/03/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.99 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 14.29% vs. Previous Quarter: -33.33% Sales Growth vs. Year Ago Period: 91.42% vs. Previous Quarter: 51.24% ROE 09/30/25 - - 06/30/25 - -68.05 03/31/25 - -62.55 ROA 09/30/25 - - 06/30/25 - -21.53 03/31/25 - -21.19 Current Ratio 09/30/25 - - 06/30/25 - 1.38 03/31/25 - 1.67 Quick Ratio 09/30/25 - - 06/30/25 - 1.38 03/31/25 - 1.67 Operating Margin 09/30/25 - - 06/30/25 - -98.92 03/31/25 - -112.83 Net Margin 09/30/25 - - 06/30/25 - -100.69 03/31/25 - -114.82 Pre-Tax Margin 09/30/25 - - 06/30/25 - -71.84 03/31/25 - -82.79 Book Value 09/30/25 - - 06/30/25 - 1.75 03/31/25 - 2.09 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.58 03/31/25 - 0.44 Debt-to-Capital 09/30/25 - - 06/30/25 - 36.51 03/31/25 - 30.52

Powered by Zacks Investment Research ©